Objective To identify an early response criterion for predicting≥ 5% weight loss with
liraglutide 3.0 mg at week 56 and to compare efficacy outcomes in early responders (ERs) …

Objective Liraglutide 3.0 mg is associated with clinically significant weight loss in clinical
trials, but real‐world data are lacking. In this analysis, weight loss and persistence outcomes …

Objective Real‐world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and
exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent …

Objective This study investigated the effectiveness of liraglutide 3.0 mg daily in combination
with a standardized multidisciplinary intervention on body weight and body composition …

Objective: Liraglutide, a once-daily human glucagon-like peptide-1 analog, induced
clinically meaningful weight loss in a phase 2 study in obese individuals without diabetes …

Objective: As an adjunct to a reduced-calorie diet and increased physical activity, treatment
with liraglutide 3.0 mg for weight management provides a statistically significant and …

Background This pilot study evaluated whether adding phentermine to liraglutide would
induce further weight loss in participants who had previously lost weight with liraglutide …

Importance Weight loss of 5% to 10% can improve type 2 diabetes and related
comorbidities. Few safe, effective weight-management drugs are currently available …

The efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to diet and exercise,
was evaluated in racial subgroups. This post hoc analysis of pooled data from five double …

Introduction: Data from randomized controlled trials show that liraglutide 3.0 mg, in
combination with diet and exercise, is associated with greater weight loss than diet and …